Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stok Raporu

Piyasa değeri: US$2.1b

Ligand Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Ligand Pharmaceuticals kazanç ve gelirinin sırasıyla yıllık 35.5% ve 15% oranında artması tahmin edilirken, EPS'nin yıllık 33.4% oranında büyümesi bekleniyor.

Anahtar bilgiler

35.5%

Kazanç büyüme oranı

33.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.8%
Gelir büyüme oranı15.0%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:LGND - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202621599911684
12/31/202518363601376
12/31/20241633422847
9/30/2024152452577N/A
6/30/202413342-448N/A
3/31/202411896-1734N/A
12/31/202313154-450N/A
9/30/2023154219095N/A
6/30/20231804199108N/A
3/31/202320451104120N/A
12/31/2022196-5120138N/A
9/30/20221832395112N/A
6/30/20221882797112N/A
3/31/202222345110120N/A
12/31/2021242767179N/A
9/30/2021275684552N/A
6/30/2021252483744N/A
3/31/2021208394248N/A
12/31/202016475155N/A
9/30/2020143-164147N/A
6/30/2020126-252428N/A
3/31/2020110-61-60-58N/A
12/31/2019120629781-29N/A
9/30/201915359481211N/A
6/30/201917467784644N/A
3/31/2019239764980179N/A
12/31/2018251143183194N/A
9/30/2018242179198193N/A
6/30/2018230120N/A193N/A
3/31/201816853N/A130N/A
12/31/201714113N/A89N/A
9/30/201712916N/A78N/A
6/30/20171179N/A69N/A
3/31/2017109-3N/A69N/A
12/31/2016109-2N/A61N/A
9/30/2016927N/A56N/A
6/30/201688205N/A48N/A
3/31/201687235N/A47N/A
12/31/201572230N/A42N/A
9/30/201574231N/A38N/A
6/30/20157133N/A32N/A
3/31/20156311N/A26N/A
12/31/20146512N/A21N/A
9/30/2014567N/A22N/A
6/30/2014548N/A18N/A
3/31/20145310N/A21N/A
12/31/2013499N/A21N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LGND 'nin tahmini kazanç büyümesi (yıllık 35.5% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: LGND şirketinin kazançlarının (yıllık 35.5% ) US pazarından (yıllık 15.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LGND şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: LGND şirketinin gelirinin (yıllık 15% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LGND şirketinin gelirinin (yıllık 15% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LGND 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin